HNSCC
Clinical trials for HNSCC explained in plain language.
Never miss a new study
Get alerted when new HNSCC trials appear
Sign up with your email to follow new studies for HNSCC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a One-Two punch of radiation and immunotherapy shrink head and neck tumors before surgery?
Disease control OngoingThis phase II trial is exploring whether combining stereotactic body radiation therapy (SBRT) with the immunotherapy drug tislelizumab, given before surgery, can help people with locally advanced head and neck squamous cell carcinoma. The study will enroll about 24 adults aged 18…
Matched conditions: HNSCC
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New cancer drug enzelkitug enters first human trials
Disease control OngoingThis early-phase trial is testing a new drug called enzelkitug, alone or with standard immunotherapies, in people with advanced solid tumors that have not responded to other treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. A…
Matched conditions: HNSCC
Phase: PHASE1 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Modified herpes virus joins forces with immunotherapy to attack head and neck tumors
Disease control OngoingThis study tests a combination of three treatments—immunotherapy (tislelizumab), targeted therapy (afatinib), and a modified herpes virus (lysogenic HSV)—given before surgery for head and neck squamous cell carcinoma. The goal is to see if this approach safely shrinks tumors and …
Matched conditions: HNSCC
Phase: PHASE1, PHASE2 • Sponsor: West China Hospital • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New combo therapy aims to fight returning head and neck cancer
Disease control OngoingThis study tests a combination of an immunotherapy drug (pembrolizumab) and a type of internal radiation (cesium-131 brachytherapy) given during surgery for head and neck cancer that has come back. The goal is to see if this approach is safe and helps prevent the cancer from retu…
Matched conditions: HNSCC
Phase: PHASE1, PHASE2 • Sponsor: University of Cincinnati • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New drug combo aims to boost immunotherapy for head and neck cancer
Disease control OngoingThis phase 2 trial tests whether adding ramucirumab to pembrolizumab (Keytruda) works better than pembrolizumab alone for people with PD-L1 positive head and neck cancer that has come back or spread. About 37 participants will receive either the combination or the single drug. Th…
Matched conditions: HNSCC
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Supercharged immune cells take on advanced cancers
Disease control OngoingThis early-phase trial tests a new approach to treat advanced solid tumors by giving patients a large dose of their own immune cells that are specially selected to attack cancer. The cells are taken from the tumor, multiplied in the lab, and then infused back. Some patients also …
Matched conditions: HNSCC
Phase: PHASE1 • Sponsor: AgonOx, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Could a drug cocktail boost survival in early oral cancer?
Disease control OngoingThis phase 2 trial tests whether adding the immunotherapy drug tirellizumab plus chemotherapy before standard surgery can improve outcomes for people with early oral squamous cell carcinoma. Sixty participants will be randomly assigned to either the drug combo plus surgery or sur…
Matched conditions: HNSCC
Phase: PHASE2 • Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
Can community navigation cut cancer delays? botswana trial aims to find out
Knowledge-focused OngoingThis study tests a program called Potlako+ that combines community education, support for healthcare providers, and patient navigation to help people with cancer symptoms get diagnosed and treated faster. About 874 participants in Botswana will be split into two groups: one recei…
Matched conditions: HNSCC
Phase: PHASE2 • Sponsor: Brigham and Women's Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:07 UTC